XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 40 Months Ended 50 Months Ended
Jul. 27, 2020
USD ($)
Sep. 30, 2020
USD ($)
Aug. 31, 2020
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
$ / shares
shares
Feb. 29, 2020
USD ($)
product_target
Sep. 30, 2019
USD ($)
Aug. 31, 2019
USD ($)
May 31, 2018
USD ($)
Apr. 30, 2018
USD ($)
milestone
Dec. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jan. 31, 2014
USD ($)
program
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
option
milestone
product_target
product
royaltyFee
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
product
milestone
Jun. 30, 2021
USD ($)
milestone
Dec. 31, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           $ 27,872,000 $ 21,553,000 $ 54,152,000 $ 34,629,000        
Other long-term liabilities                           7,425,000   7,425,000   $ 7,011,000   $ 7,425,000  
California institute for regenerative medicine agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Funds due under the agreement                 $ 8,000,000.0                        
Other long-term liabilities                           6,800,000   6,800,000   6,400,000   6,800,000  
California institute for regenerative medicine agreement | Research grants                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                               5,200,000          
Novartis Institutes for BioMedical Research, Inc.                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           9,581,000 0 17,442,000 0        
Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           7,559,000 0 13,759,000 0        
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Proceeds from collaborators     $ 75,000,000.0                             75,000,000.0      
Collaborative arrangement transaction price $ 95,100,000                                        
License fee 75,000,000.0                                        
Collaborative arrangement estimated reimbursable service costs 20,100,000                                        
Deferred revenue                           57,100,000   57,100,000   70,900,000   57,100,000  
Financial advisory fees                                   $ 1,500,000      
Percent of initial recognition                                   2.00%      
Amortization                           200,000   300,000          
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of specified preclinical development clinical development and first commercial sale milestones                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received 420,000,000.0                                        
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of commercial milestones                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received $ 300,000,000.0                                        
Biogen MA, Inc.                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           10,767,000 8,178,000 21,217,000 8,178,000        
Biogen MA, Inc. | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           7,306,000 6,744,000 14,612,000 6,744,000        
Biogen MA, Inc. | Collaboration and license agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Proceeds from collaborators       $ 125,000,000.0                           $ 125,000,000.0      
Financial advisory fees                                   $ 7,000,000.0      
Percent of initial recognition                                   2.00%      
Amortization                           200,000 0 $ 300,000 0        
Maximum milestone payment receivable           $ 2,370,000,000                              
Number of product targets | product_target           12                              
Number of additional product targets | product_target           9                              
Target selection period           5 years                              
Number of product targets selected | product_target           3                              
Research period           7 years                              
Maximum number of product targets replaced | product_target                               10          
Portion of contract asset recognized                                   $ 4,100,000      
Consideration received on transaction                                   204,600,000      
Biogen MA, Inc. | Collaboration and license agreement | Pre-approval milestone                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Maximum milestone payment receivable           $ 925,000,000.0                              
Biogen MA, Inc. | Collaboration and license agreement | Sales-based milestone                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Maximum milestone payment receivable           $ 1,450,000,000                              
Biogen MA, Inc. | Stock purchase agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Deferred revenue                           168,600,000   $ 168,600,000   183,200,000   168,600,000  
Number of shares issued in transaction (in shares) | shares         24,420,157                                
Sale of stock, price per share (in dollars per share) | $ / shares         $ 9.2137                                
Aggregate purchase price         $ 204,600,000                                
Standstill restriction period           3 years                              
Standstill restriction, ownership threshold percentage ownership percentage           5.00%                              
Agreement restriction, percentage of shares held           50.00%                              
Voting provisions expiration period           2 years                              
Voting provisions, ownership threshold percentage           5.00%                              
Excess consideration received on transaction                                   79,600,000      
Consideration received on transaction                                   225,000,000.0      
Recognized portion of equity issued                                   2,900,000      
Collaboration agreement, equity issued                                   145,400,000      
Kite Pharma, Inc.                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           6,324,000 7,422,000 12,612,000 14,641,000        
Kite Pharma, Inc. | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           6,227,000 6,227,000 12,386,000 12,454,000        
Kite Pharma, Inc. | Collaboration and license agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                   $ 3,010,000,000.00                      
Collaborative arrangement transaction price             $ 189,300,000                            
Collaborative arrangement estimated reimbursable service costs                           39,300,000              
Deferred revenue                           69,000,000.0   $ 69,000,000.0   81,400,000   69,000,000.0  
Milestone payments received                   150,000,000.0                      
Initial research term of agreement                               6 years          
Number of options to extend initial research term | option                               2          
Extended research term of agreement                               1 year          
Separate upfront fee                               $ 10,000,000.0          
Collaborative arrangement estimated reimbursable service costs for new research plan             $ 3,400,000                            
Revenues under agreement                           150,000,000.0              
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Contingent development - and sales-based milestone payments to be received                   1,260,000,000                      
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Contingent development - and sales-based milestone payments to be received                   $ 1,750,000,000                      
Maximum amount of achieved milestones to receive payment | milestone                   10                      
Pfizer Inc.                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone payments received                     $ 12,000,000.0                    
Revenues                           0   $ 0          
Pfizer Inc. | SB-525 and other products                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues under agreement                       $ 70,000,000.0                  
Potential amount to be funded for achievement of specified commercialized and sales milestones                       266,500,000                  
Pfizer Inc. | SB-525                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone revenue receivable                       300,000,000.0                  
Pfizer Inc. | Other products                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone revenue receivable                       175,000,000.0                  
Pfizer Inc. | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                             3,400,000   3,800,000        
Pfizer Inc. | C9ORF72                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                                     $ 5,000,000.0    
Collaborative arrangement transaction price                     17,000,000.0                    
Milestone payments received                     12,000,000.0                    
Revenues under agreement   $ 5,000,000.0                 5,000,000.0                    
Agreement termination, term                               15 years          
Number of products approved | product                                     0    
Number of milestones included in transaction price | milestone                                     0    
Pfizer Inc. | Achievement of specified preclinical development clinical development and first commercial sale milestones | C9ORF72                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                     60,000,000.0                    
Pfizer Inc. | Achievement of commercial milestones | C9ORF72                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                     $ 90,000,000.0                    
Pfizer Inc. | Achievement of specified clinical development intellectual property and regulatory milestones | SB-525 and other products                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                       208,500,000                  
Pfizer Inc. | Achievement of first commercial sale milestones | SB-525 and other products                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                       $ 475,000,000.0                  
Pfizer SB-525                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Collaborative arrangement transaction price                               $ 134,000,000.0          
Revenues under agreement                               $ 55,000,000.0          
Agreement termination, term                               15 years          
Research service fees                               $ 79,000,000.0          
Revenues                           0   $ 0          
Pfizer SB-525 | SB-525 and other products                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone payments received                                       $ 55,000,000.0  
Number of milestones achieved | milestone                                       2  
Number of products approved | product                               0          
Number of milestones included in transaction price | royaltyFee                               0          
Pfizer SB-525 | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Cumulative milestone achieved                             300,000   2,500,000        
Pfizer SB-525 | Milestone achievement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Cumulative milestone achieved                             100,000   1,100,000        
Sanofi                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues under agreement                         $ 20,000,000.0                
Agreement termination, term                               180 days          
Milestone revenue receivable                           6,000,000.0   $ 6,000,000.0       $ 6,000,000.0  
Number of products approved | product                               0          
Revenues                           957,000 1,792,000 $ 2,017,000 2,291,000        
Number of research programs | program                         2                
Sanofi | Recognition of license and stand-ready fee                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           206,000 380,000 433,000 (349,000)        
Sanofi | Milestone achievement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Revenues                           138,000 $ 257,000 292,000 $ (235,000)        
Sanofi | Collaboration and license agreement                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                         $ 276,300,000                
Collaborative arrangement transaction price                         93,300,000                
Collaborative arrangement estimated reimbursable service costs                         59,800,000                
Deferred revenue                           500,000   $ 500,000   $ 1,200,000   500,000  
Revenues under agreement                         20,000,000.0                
Number of milestones included in transaction price | milestone                               0          
Cumulative milestone achieved                               $ 7,400,000          
Sanofi | Collaboration and license agreement | Milestone two                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone revenue receivable                           7,500,000   7,500,000       7,500,000 $ 7,500,000
Milestone revenue reversal                           100,000   200,000          
Sanofi | Collaboration and license agreement | Milestone three                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone revenue receivable                           13,500,000   13,500,000       $ 13,500,000  
Sanofi | Collaboration and license agreement | ST-40 Beta Thalassemia Phase 1 clinical trial milestone                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Milestone payments received               $ 6,000,000.0                          
Cumulative milestone achieved                               5,900,000          
Milestone revenue reversal                           $ 100,000   $ 100,000          
Sanofi | Collaboration and license agreement | Achievement of specified clinical development And regulatory milestones                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                         115,800,000                
Sanofi | Collaboration and license agreement | Achievement of specified sales milestones                                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                          
Development and sales-based milestone payments to be received                         $ 160,500,000